Noevir Holdings Co., Ltd. (JP:4928)
:4928
Top Page
Noevir Holdings Co., Ltd.
(4928)
Select Model
Select Model
Rating:72Outperform
Price Target:
¥5,112.00
▲(11.62% Upside)
Action:ReiteratedDate:12/11/25
Noevir Holdings earns an overall score of 72, driven primarily by strong financial performance with a robust balance sheet and solid profitability, though tempered by modest growth and cash flow concerns. Technical analysis supports a moderate bullish trend, and valuation metrics indicate a fair price with an attractive dividend yield. Financial stability remains the most significant factor in this assessment.
Positive Factors
Revenue Growth
Consistent revenue growth indicates a strong market position and effective product strategy, supporting long-term business sustainability.
Negative Factors
Free Cash Flow Growth Challenges
Negative free cash flow growth can limit the company's ability to invest in new opportunities and may impact long-term financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates a strong market position and effective product strategy, supporting long-term business sustainability.
Read all positive factors
Noevir Holdings Co., Ltd. (4928) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥153.87B
Dividend Yield5%
Average Volume (3M)162.01K
Price to Earnings (P/E)29.6
Beta (1Y)0.43
Revenue Growth1.41%
EPS Growth0.75%
CountryJP
Employees1,369
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)38.70
Shares Outstanding34,156,624
10 Day Avg. Volume82,960
30 Day Avg. Volume162,006
Financial Highlights & Ratios
PEG Ratio25.18
Price to Book (P/B)2.84
Price to Sales (P/S)2.36
P/FCF Ratio26.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)237.1
Revenue Forecast (FY)¥65.15B
Noevir Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
Noevir Holdings Co., Ltd. develops, produces, and sells cosmetics, pharmaceuticals, and health food products in Japan, China, Taiwan, South Korea, Hong Kong, Singapore, Thailand, the United States, Canada, and Russia. The company's Cosmetics segme...
How the Company Makes Money
Noevir Holdings generates revenue primarily through the sale of its cosmetic products, health supplements, and pharmaceuticals. The company operates a multi-channel distribution model, including direct sales through its network of sales representa...
Noevir Holdings Co., Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
85
Very Positive
Cash Flow
65
Positive
| Breakdown | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 64.72B | 63.82B | 62.55B | 61.14B | 51.27B |
| Gross Profit | 43.28B | 43.16B | 42.56B | 42.09B | 33.03B |
| EBITDA | 11.94B | 12.44B | 12.24B | 11.57B | 10.05B |
| Net Income | 8.03B | 7.97B | 7.67B | 7.59B | 6.38B |
Balance Sheet | |||||
| Total Assets | 76.49B | 76.47B | 77.25B | 76.78B | 80.45B |
| Cash, Cash Equivalents and Short-Term Investments | 26.93B | 29.22B | 28.88B | 29.75B | 31.10B |
| Total Debt | 742.00M | 828.00M | 914.00M | 1.00B | 1.11B |
| Total Liabilities | 22.28B | 22.56B | 24.04B | 24.39B | 28.21B |
| Stockholders Equity | 53.77B | 53.48B | 52.79B | 52.06B | 51.93B |
Cash Flow | |||||
| Free Cash Flow | 5.66B | 8.50B | 6.89B | 5.30B | 8.69B |
| Operating Cash Flow | 7.93B | 9.12B | 7.62B | 5.84B | 9.06B |
| Investing Cash Flow | -2.42B | 1.52B | -3.54B | -255.00M | -416.00M |
| Financing Cash Flow | -7.92B | -7.71B | -7.49B | -7.38B | -7.18B |
Noevir Holdings Co., Ltd. Technical Analysis
Negative
4580.00
Price Trends
4605.80
Negative
4605.85
Negative
4471.18
Positive
Market Momentum
-18.84
Negative
46.15
Neutral
71.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4928, the sentiment is Negative. The current price of 4580 is above the 20-day moving average (MA) of 4542.75, below the 50-day MA of 4605.80, and above the 200-day MA of 4471.18, indicating a neutral trend. The MACD of -18.84 indicates Negative momentum. The RSI at 46.15 is Neutral, neither overbought nor oversold. The STOCH value of 71.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4928.
Noevir Holdings Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥153.87B | 29.58 | ― | 5.00% | 1.41% | 0.75% | |
70 Outperform | ¥2.78T | 24.05 | 11.50% | 2.41% | 4.62% | 47.68% | |
69 Neutral | ¥338.02B | 13.05 | 2.72% | 2.61% | 1.37% | -5.60% | |
69 Neutral | ¥297.44B | 30.42 | 5.84% | 3.92% | -1.16% | 36.30% | |
63 Neutral | ¥138.78B | 62.64 | 3.10% | 1.45% | 3.95% | -25.42% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | ¥1.39T | -22.37 | ― | 2.11% | -1.20% | -2896.72% |
* Consumer Defensive Sector Average
JP:4928
Noevir Holdings Co., Ltd.
4,505.00
570.84
14.51%
JP:4452
Kao
6,148.00
64.00
1.05%
JP:4922
Kose
5,925.00
124.68
2.15%
JP:4917
Mandom
3,085.00
1,796.00
139.33%
JP:4927
Pola Orbis Holdings
1,344.50
99.50
7.99%
JP:4911
Shiseido Company,Limited
3,472.00
969.70
38.75%
Noevir Holdings Co., Ltd. Corporate Events
Noevir Holdings Announces Shareholder Details and Minority Protection Measures
Dec 9, 2025
Noevir Holdings Co., Ltd. announced details regarding its controlling shareholders, highlighting that Takashi Okura holds a significant portion of voting rights. The company emphasizes its commitment to fair transactions with its controlling share...
Noevir Holdings Announces Key Leadership Changes
Dec 9, 2025
Noevir Holdings Co., Ltd. announced significant changes in its leadership structure to enhance its management capabilities. The appointment of Ikkou Yoshida as Vice President and Representative Director is part of the company’s strategy to s...
Noevir Holdings Announces Leadership Restructuring in Subsidiaries
Nov 7, 2025
Noevir Holdings Co., Ltd. has announced changes in the leadership of its subsidiaries, Noevir Co., Ltd. and TOKIWA Pharmaceutical Co., Ltd., as part of a management restructuring. These changes, which will be finalized at upcoming shareholder and ...
Noevir Holdings Proposes Flexible Meeting Amendments
Nov 7, 2025
Noevir Holdings Co., Ltd. has announced a proposed amendment to its Articles of Incorporation to allow for the holding of General Meetings of Shareholders without a fixed location. This change is aimed at reducing risks associated with large-scale...
Noevir Holdings Increases Year-End Dividend Payout
Nov 7, 2025
Noevir Holdings has announced an increase in its year-end dividend distribution from retained earnings, raising the dividend per share to 230 yen, up from the previous 225 yen. This decision reflects the company’s policy of consistently retu...
Noevir Holdings Reports Steady Financial Performance for 2025
Nov 7, 2025
Noevir Holdings reported a slight increase in net sales and net income for the fiscal year ending September 30, 2025, despite a decline in operating income. The company maintained a stable financial position with a slight improvement in equity rat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.